Literature DB >> 15858113

Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.

M R Hussein1.   

Abstract

Although several studies have confirmed the aetiological importance of melanocytic dysplastic naevi (MDN) in the development of cutaneous malignant melanoma (CMM), the analysis of these lesions was directed mostly towards the study of melanomas. The underlying reasons include the relatively large size of CMMs, their direct lethal outcome, and the feasibility of establishing melanoma cell lines. In contrast, because of their relatively small size, questionable malignant potential, and the difficulty in establishing in vitro cultures, MDN have been studied less extensively. Hypothetically, transformed melanocytes can give rise to any lesion in the hierarchy of melanocytic tumours. Based on this hypothetical perspective, and on the epidemiological, morphological, immunohistochemical, and genetic characteristics of MDN, it is not surprising that these lesions occupy an intermediate position in the hierarchy of melanocytic lesions, and may be precursors of CMM. Although this argument appears to be straightforward, it is still controversial. This review explores the components of this argument and provides supporting evidence for this hypothesis.

Entities:  

Mesh:

Year:  2005        PMID: 15858113      PMCID: PMC1770661          DOI: 10.1136/jcp.2004.019422

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  46 in total

1.  Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study.

Authors:  A C Halpern; D Guerry; D E Elder; W H Clark; M Synnestvedt; S Norman; R Ayerle
Journal:  Arch Dermatol       Date:  1991-07

2.  The ultrastructure of dysplastic naevi: comparison with superficial spreading melanoma and common naevocellular naevi.

Authors:  K Langer; K Rappersberger; A Steiner; K Konrad; K Wolff
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

3.  A transmission electron microscopical study of dysplastic naevi.

Authors:  H Beitner; T Nakatani; M A Hedblad
Journal:  Acta Derm Venereol       Date:  1990       Impact factor: 4.437

Review 4.  An exchange of ideas about dysplastic nevi and malignant melanomas.

Authors:  A B Ackerman; D E Elder
Journal:  Am J Dermatopathol       Date:  1985       Impact factor: 1.533

5.  Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody.

Authors:  H Takahashi; G M Strutton; P G Parsons
Journal:  Histopathology       Date:  1991-03       Impact factor: 5.087

6.  p53 Protein expression in nevi and melanomas.

Authors:  M Cristofolini; S Boi; S Girlando; G Zumiani; P Cristofolini; P Dalla Palma; C Doglioni; M Barbareschi
Journal:  Arch Dermatol       Date:  1993-06

7.  HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma.

Authors:  B R Smoller; N S McNutt; A Hsu
Journal:  Am J Surg Pathol       Date:  1989-08       Impact factor: 6.394

8.  Overexpression of p53 is a late event in the development of malignant melanoma.

Authors:  N J Lassam; L From; H J Kahn
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

9.  Clues to the pathogenesis of familial colorectal cancer.

Authors:  L A Aaltonen; P Peltomäki; F S Leach; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; S M Powell; J Jen; S R Hamilton
Journal:  Science       Date:  1993-05-07       Impact factor: 47.728

10.  The flow cytometry of melanocytic skin lesions.

Authors:  J A Newton; R S Camplejohn; D H McGibbon
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

View more
  9 in total

1.  Expression of Bcl-2, Melan A and HMB-45 in Dysplastic Nevi.

Authors:  Oana Maria Patrascu; Mariana Costache; Adrian Vasile Dumitru; Corina Nicoleta Mehotin; Maria Sajin; Anca Mihaela Lazaroiu
Journal:  Maedica (Bucur)       Date:  2016-03

2.  Mutational status of naevus-associated melanomas.

Authors:  D Shitara; G Tell-Martí; C Badenas; M M S S Enokihara; L Alós; A B Larque; N Michalany; J A Puig-Butille; C Carrera; J Malvehy; S Puig; E Bagatin
Journal:  Br J Dermatol       Date:  2015-06-19       Impact factor: 9.302

3.  Reduced GNG2 expression levels in mouse malignant melanomas and human melanoma cell lines.

Authors:  Ichiro Yajima; Mayuko Y Kumasaka; Yuji Naito; Toshikazu Yoshikawa; Hiro Takahashi; Yoko Funasaka; Tamio Suzuki; Masashi Kato
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

4.  c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines.

Authors:  Yuichiro Ohshima; Ichiro Yajima; Kozue Takeda; Machiko Iida; Mayuko Kumasaka; Yoshinari Matsumoto; Masashi Kato
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

Review 5.  Melanocytic nevi simulant of melanoma with medicolegal relevance.

Authors:  Guido Massi
Journal:  Virchows Arch       Date:  2007-07-26       Impact factor: 4.064

6.  NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.

Authors:  Philipp Tschandl; Anna Sophie Berghoff; Matthias Preusser; Sebastian Burgstaller-Muehlbacher; Hubert Pehamberger; Ichiro Okamoto; Harald Kittler
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

Review 7.  Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.

Authors:  Hassan Sadozai; Thomas Gruber; Robert Emil Hunger; Mirjam Schenk
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

8.  Management of melanoma families.

Authors:  Wilma Bergman; Nelleke A Gruis
Journal:  Cancers (Basel)       Date:  2010-04-16       Impact factor: 6.639

Review 9.  Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review.

Authors:  Piyu Parth Naik
Journal:  Dermatol Ther (Heidelb)       Date:  2021-08-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.